Pramine
Dysthymic Disorder
New York State Psychiatric InstituteSmall moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Dysthymic Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Escitalopram Nova Scotia Health Authority | Phase 4 | BBB |
Fluoxetine New York State Psychiatric Institute | Phase 4 | BB |
Desvenlafaxine New York State Psychiatric Institute | Phase 4 | BB |
VENLOR University of Washington | Phase 4 | BB |
Armodafinil Cephalon | Phase 4 | BB |
View all 13 →
Same molecule, other indications
Pramine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →